Abcam, ab249506, Anti-B3GALT4 antibody [EPR11650] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal B3GALT4 antibody. Carrier free. Suitable for IHC-P, WB, Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR11650,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Flow Cyt (Intra), WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249506 is the carrier-free version of
ab169759
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
B3GALT4 also known as beta-13-galactosyltransferase-4 is a glycosyltransferase enzyme that plays an important role in glycosylation processes. This enzyme facilitates the transfer of galactose from UDP-galactose to the terminal N-acetylglucosamine of glycoproteins and glycolipids forming a beta-13 bond. B3GALT4 has a molecular mass of approximately 42 kDa. Expression of B3GALT4 occurs in various tissues including the brain liver and kidney indicating its extensive involvement across different physiological systems.
Biological function summary
The enzyme B3GALT4 contributes to the synthesis of glycan structures. It participates in the glycosphingolipid biosynthesis pathway where it has involvement in the addition of galactose to lactosylceramide. By doing so B3GALT4 helps in transforming lactosylceramide into more complex glycolipids which are components of cell membranes and mediate cell-cell interactions. This enzyme is not known as part of a larger complex but it acts independently within the glycosylation machinery.
Pathways
B3GALT4 functions within the glycosphingolipid metabolism and the N-glycan biosynthesis pathways. It contributes to the complexity and diversity of glycan structures that are key in these pathways. B3GALT4 interacts with other glycosyltransferases such as beta-14-galactosyltransferase in orchestrating the stepwise extension of oligosaccharide chains. Understanding these pathways offers insight into how B3GALT4 contributes to essential cellular functions like cell signaling and immune response.
B3GALT4 dysregulation associates with GM1 gangliosidosis and Morquio syndrome type B. GM1 gangliosidosis results from the accumulation of GM1 gangliosides due to insufficient breakdown often influenced by abnormal glycosylation from B3GALT4 activity. This disorder connects B3GALT4 with the lysosomal enzyme beta-galactosidase which is directly involved in degrading glycolipids. In Morquio syndrome type B mutations impacting glycosylation pathways suggest an indirect link to B3GALT4's enzymatic processes ultimately contributing to skeletal abnormalities.